SK Bioscience opens Korea’s largest vaccine R&D center in Incheon

SK Bioscience on Monday completed its relocation to its new headquarters in Incheon, as the company seeks to transform its Songdo base from a manufacturing-centered site into an advanced research hub. The company said operations have begun at its Research & Process Development Center in Songdo, Incheon. SK Bioscience invested 377.2 billion won ($256 million) in the facility, which enables vaccine research, process development and quality analysis to be conducted within a single, integrated development flow. SK Bioscience said the center is the largest facility in Korea dedicated to vaccine research, housing specialized laboratories for next-generation vaccine platforms, including messenger RNA, recombinant protein and viral vector technologies. At the center, the company plans to strengthen its existing portfolio, including influenza and pneumococcal vaccines, while expanding its vaccine platforms. It also aims to pursue mid- to long-term strategies, such as expanding global joint projects with international organizations including the Coalition for Epidemic Preparedness Innovations, thWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times